BRIEF-Biogen, Eisai scrap Alzheimer's drug trials
March 21 (Reuters) - Biogen Inc:
* BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER’S DISEASE
* BIOGEN INC - INDEPENDENT DATA MONITORING COMMITTEE ADVISES ADUCANUMAB UNLIKELY TO MEET PRIMARY ENDPOINTS, LEADING TO DECISION TO DISCONTINUE TRIALS
* BIOGEN INC - DECISION TO STOP TRIALS IS BASED ON RESULTS OF A FUTILITY ANALYSIS CONDUCTED BY AN INDEPENDENT DATA MONITORING COMMITTEE
* BIOGEN - AS PART OF THIS DECISION, EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED
* BIOGEN INC - RESULTS INDICATED TRIALS WERE UNLIKELY TO MEET PRIMARY ENDPOINT UPON COMPLETION
* BIOGEN INC - INITIATION OF ADUCANUMAB PHASE 3 SECONDARY PREVENTION TRIAL WILL BE ASSESSED WHILE DATA FROM ENGAGE AND EMERGE ARE FURTHER EVALUATED
* BIOGEN INC - RECOMMENDATION TO STOP STUDIES WAS NOT BASED ON SAFETY CONCERNS.
* BIOGEN INC - EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED
* BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage:
